• March 24, 2023

  EISAI TO PRESENT RESEARCH FROM ONCOLOGY PORTFOLIO AT THE SOCIETY OF GYNECOLOGIC ONCOLOGY (SGO) 2023 ANNUAL MEETING ON WOMEN’S CANCER

• March 23, 2023

  EISAI TO PRESENT NEW LECANEMAB DATA, INCLUDING RESEARCH EVALUATING SAFETY PROFILE, CLINICAL OUTCOMES AND QUALITY OF LIFE MEASURES, AS WELL AS OTHER IMPORTANT ALZHEIMER’S DISEASE RESEARCH, AT THE AD/PD™ 2023 ANNUAL MEETING
  Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Patients from Eisai’s Lecanemab Phase 3 Confirmatory Clarity AD Study in Early Alzheimer’s Disease

• March 20, 2023

  EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL

• March 14, 2023

  U.S. VETERANS’ HEALTH ADMINISTRATION (VHA) PROVIDES COVERAGE OF LEQEMBI™ (LECANEMAB-IRMB) TWO MONTHS AFTER LEQEMBI’S FDA ACCELERATED APPROVAL FOR VETERANS LIVING WITH EARLY STAGES OF ALZHEIMER’S DISEASE
  EISAI IS PROUD TO SUPPORT U.S. VETERANS LIVING WITH EARLY STAGES OF ALZHEIMER’S DISEASE AND WILL CONTINUE TO TRANSPARENTLY SHARE OUR HIGH-QUALITY DATA WITH THE VHA

• March 10, 2023

  EISAI RECEIVES THE “BASIC ACHIEVEMENT GRAND PRIZE” AT THE 2023 J-WIN DIVERSITY AWARD

View All

• March 13, 2023

  IR “Information Meeting 2023 [Material, Webcast]”

• March 9, 2023

  IR “Presentation Material for Press Conference 2023”

• February 13, 2023

  Sustainability "World NTD Day Event Held in Japan ー Roadmap for Achieving SDGs and Eliminating NTDs in 2030"

• February 7, 2023

  IR “Third Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2023 [Material, Webcast]”

• February 6, 2023

  IR “Third Quarter Financial Report for the Fiscal Year Ending March 31, 2023”

View All

• March 9, 2023

  Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties

• February 17, 2023

  EISAI SUPPORTS RELIEF EFFORTS FOR EARTHQUAKE IN TURKEY AND SYRIA

• July 15, 2022

  Notification Regarding U.S. Research and Development Subsidiary

• April 1, 2022

  Humanitarian Support to Ukraine

• November 24, 2021

  Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

View All